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The association of neurofibromatosis type I with invasive male breast cancer is a rare clinical entity with only one
case in literature reported in 1953. Women with NF1 are at risk of developing breast cancer and men also may be
at risk but there is scarce data on the risk and association of NF1 with male breast cancer due to its rarity.
Established clinical trials in male breast cancer patients are lacking and the results are extrapolated from female
breast cancer patients. The treatment of male breast cancer is followed as per the guidelines of premenopausal
female breast cancer and tamoxifen is the hormone treatment in them. Mendes et al suggests that silencing of NF1
gene confers resistance to tamoxifen. Our conclusions are that since NF1 is mutated or deleted in one third of
sporadic breast cancers, its role as a molecular driver for treatment has to be further explored.Introduction
Male breast cancer is a rare disease and accounts for less
than 1% of all breast cancers [1]. Neurofibromatosis type 1
(NF1) or Von Recklinghausen disease is an autosomal dom-
inant condition that leads to multiple benign tumors (neuro-
fibromas) and predisposes to several types of malignancies,
including breast cancer. To the best of our knowledge, only
1 case of neurofibromatosis in a male patient with breast
cancer has been previously reported in the literature [2].
Here we report another case and discuss the potential role
of the NF1 gene in the pathogenesis of these cases.Case description
A 55-year-old male presented to our institution in
November 2011 with complaints of multiple skin nodules,
brown skin patches since childhood and an enlarging pain-
less lump in the left breast for 2 months. There was no other
medical history of relevance including food allergies or drug
abuse. There was history of similar skin nodules in his
brother and paternal uncle. There was no history of breast,
ovary or prostate cancer in the family.* Correspondence: kcluck@gmail.com
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distribution, and reproduction in any mediumOn examination, multiple, soft, sessile to pedunculated,
dome shaped, skin colored nodules (Figure 1) with size
ranging from 0.5-4 cms and eight well circumscribed
brown macular patches distributed all over the body, with
size ranging from 0.5-6 cms, were observed. On ophthal-
mologic examination, the iris and retina were normal. An
irregular lump in left breast of size 6 × 2 cms was noted.
It was hard in consistency, non-tender, and mobile; axil-
lary lymph nodes were not palpable. Hematological, renal
and liver function tests were normal.
Fine needle aspiration from the lump was suggestive of
ductal carcinoma. Genetic analyses could not be con-
ducted for financial/logistics reasons and the diagnosis of
NF1 was made based on clinical criteria [3]. Hence a diag-
nosis of NF1 and breast cancer was made. After staging
workup, the patient underwent modified radical mastec-
tomy and axillary lymph node dissection. Histopatho-
logical examination revealed invasive ductal carcinoma of
Bloom and Richardson histological grade III (Figure 2).
The pathological stage was pT3N0M0. On immunohisto-
chemistry, estrogen and progesterone receptors (ER, PgR)
were both positive and HER2 was negative (Figure 3).
The patient received 6 cycles of adjuvant FEC (fluoro-
uracil 500 mg/m2 q3w, epirubicin 100 mg/m2 q3w,
cyclophosphamide 500 mg/m2 q3w) chemotherapy
followed by external beam radiotherapy on a cobalt-60ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
Figure 1 Clinical photograph of male patient with multiple sessile
to pedunculated, dome shaped, skin colored nodules, multiple
cafe-u-lait spots, and a left modified radical mastectomy scar.
Figure 2 High magnification of invasive ductal carcinoma of breast w
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supraclavicular fields of 50 Gy in 25 fractions with 2 Gy
per fraction given once a day for 5 weeks.
At present, the patient is receiving tamoxifen 20 mg
once daily and is on follow up since 8 months.
Discussion
NF1 is an autosomal dominant Mendelian syndrome oc-
curring in about 1 in 4000 persons in the general popu-
lation and has high penetrance but wide variability in
expression [4]. It represents a risk factor for the develop-
ment of various malignancies, including female breast
cancer [5].
Neurofibromin 1 (NF1) is a tumor suppressor gene
that encodes the neurofibromin protein, a negative regu-
lator of the Ras oncogene. NF1 is located on the pericen-
tromeric region of the long arm of chromosome 17
(which interestingly also houses the BRCA1 gene), and
regulates the conversion of the active Ras-GTP to in-
active Ras-GDP (Figure 4) [6]. About 28% of sporadic
breast cancers in humans are missing at least one copy
of NF1 gene, either due to deletion or mutation [7].
According to Knudson’s “two-hit” hypothesis, both al-
leles have to be inactivated for tumorogenesis to occur.
In NF1-associated cancers, the first “hit” is a germline
mutation, while the second “hit” is a somatic mutation
that occurs either in utero or after birth and results in
inactivation of the normal NF1 allele and a consequent
loss of neurofibromin function. Both alleles of NF1
need to be inactivated to influence carcinogenesis, but
there is emerging evidence that haploinsuficiency or re-
duced expression may also have a functional impact [8].ith tumor nests and marked nuclear pleomorphism.
Figure 3 Intense ER immunolabelling in tumor nuclei.
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tion. Mutation in the normal copy of the NF1 gene en-
hances the risk of cancer among NF1 patients but these
mutations may also be observed in sporadic tumors [9,10].
Women with inherited NF1 deficiency have an increased
risk of breast cancer [11,12]. Some reports implicate spon-
taneous NF1 loss in breast tumorigenesis [13,14]. A recent
report suggests that females with NF1 have a relative riskFigure 4 The NF1 gene is a negative regulator of Ras, and thus impacof 2.3 (95% confidence interval 1.7 to 2.9) for developing
breast cancer compared with a reference cohort [5]. Men
also may be at risk (as highlighted by this case report) but
there is scarce data on the risk and association of NF1 and
male breast cancer due to its rarity [15].
Silencing NF1 (or other genes including, BAP1, CDK10,
NIPBL, PTEN, RARG, SMC3, and UBA3) have been shown
to confer tamoxifen resistance in human breast cancerts key breast cancer signaling pathways.
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for hormone receptor positive breast cancers, may theoretic-
ally be less effective in cancers involving NF1 mutations;
however, this needs to be corroborated by clinical evidence.
In conclusion, this report aims to describe a rare presenta-
tion of a male patient with NF1 and breast cancer. The NF1
gene is mutated or deleted in a significant proportion of hu-
man breast cancers, and its role as a potentially important
molecular driver in breast cancers needs to be explored fur-
ther. One can speculate that drugs blocking the Ras pathway
could be useful in breast cancer with NF1 mutations; this hy-
pothesis needs to be tested in a scientifically robust manner.Consent
Informed consent has been obtained from the patient
for publication.
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